AKRO
Akero Therapeutics, Inc. · Healthcare · Biotechnology
Last
$54.65
+$0.10 (+0.18%) 4:00 PM ET
Prev close $54.55
Open $54.53
Day high $54.81
Day low $54.37
Volume 13,252,100
Avg vol 2,152,967
Sector
Healthcare
AI report sections
AKRO
Akero Therapeutics, Inc.
No AI report section text found yet for this symbol.
AI summarized at 11:01 PM ET, 2025-05-20
Volume vs average
Intraday (cumulative)
−100% (Below avg)
Vol/Avg: 0.00×
RSI
72.43 (Overbought)
Overbought (>70)
MACD momentum
Intraday
+0.00 (Neutral)
MACD: 0.00 Signal: 0.00
Short-Term
-0.12 (Weak)
MACD: 0.48 Signal: 0.60
Long-Term
-0.19 (Weak)
MACD: 1.82 Signal: 2.02
Intraday trend score 63.00

Latest news

AKRO 12 articles Positive: 6 Neutral: 6 Negative: 0
Neutral GlobeNewswire Inc. • Halper Sadeh Llc
Halper Sadeh LLC Encourages SEE, AXTA, SEMR, AKRO Shareholders to Contact the Firm to Discuss Their Rights

Law firm investigating potential securities law violations and fiduciary duty breaches for several companies involved in recent merger and acquisition transactions.

SEE AXTA SEMR AKRO securities law mergers acquisitions shareholder rights
Sentiment note

Being sold to Novo Nordisk with cash payment and contingent value right, subject to legal investigation

Positive Benzinga • Juan Monteverde
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-HOUS, CRTAF, BRY, and AKRO

Law firm Monteverde & Associates is investigating potential merger-related class action lawsuits for several companies, including Anywhere Real Estate, Cartica Acquisition, Berry Corporation, and Akero Therapeutics.

HOUS BRY AKRO merger shareholder class action investigation
Sentiment note

Proposed sale to Novo Nordisk with cash payment of $54.00 per share and potential additional $6.00 contingent value right

Neutral GlobeNewswire Inc. • Halper Sadeh Llc
Halper Sadeh LLC Encourages JAMF, CADE, AKRO, GES Shareholders to Contact the Firm to Discuss Their Rights

Law firm Halper Sadeh LLC is investigating potential securities law violations and breaches of fiduciary duties for several companies undergoing mergers and acquisitions.

JAMF CADE CADEPA AKRO securities law mergers acquisitions shareholder rights
Sentiment note

Being acquired by Novo Nordisk with cash payment and contingent value right

Neutral GlobeNewswire Inc. • Brodsky & Smith
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD)

Law firm Brodsky & Smith is investigating potential breaches of fiduciary duties by boards of several companies during merger and acquisition processes, focusing on whether shareholders are receiving fair value.

QRVO FFWM AKRO mergers acquisitions shareholder investigations fiduciary duties
Sentiment note

Novo Nordisk acquisition includes cash payment and contingent value right, but investigation suggests potential valuation concerns

Positive GlobeNewswire Inc. • Novo Nordisk
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

Novo Nordisk reported 12% sales growth in Q3 2025, with strong performance in Obesity and Diabetes care. The company is undergoing a transformation, incurring restructuring costs, and adjusting growth expectations for GLP-1 treatments.

NVO AKRO OMER MTSR financial results obesity diabetes R&D
Sentiment note

Being acquired by Novo Nordisk, indicating potential value in their MASH treatment pipeline

Positive GlobeNewswire Inc. • Halper Sadeh Llc
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches in several corporate sales involving trueCar, Akero Therapeutics, PotlatchDeltic, and Astria Therapeutics.

TRUE AKRO PCH ATXS shareholder rights securities law corporate sales mergers
Sentiment note

Sale to Novo Nordisk with cash payment of $54.00 per share and additional contingent value right

Neutral GlobeNewswire Inc. • Brodsky & Smith
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL)

Law firm Brodsky & Smith is investigating potential breaches of fiduciary duties by boards of several companies during merger and acquisition processes, focusing on whether shareholders are receiving fair value.

AKRO CCRD AL PBBK mergers acquisitions shareholder investigations fiduciary duties
Sentiment note

Being acquired by Novo Nordisk for $54.00 per share with potential additional $6.00 CVR, but investigation suggests potential undervaluation

Positive Investing.com • Chris Markoch
Novo Nordisk Stock Seen Undervalued Despite Pullback and 2026 Growth Focus

Novo Nordisk plans to acquire Akero Therapeutics for $4.7 billion, expanding its obesity and metabolic health treatment portfolio. The company is positioning itself competitively in the GLP-1 drug market, with an expected market growth from $15 billion in 2024 to $150 billion by 2034.

NVO LLY AKRO obesity GLP-1 drugs metabolic health weight loss pharmaceutical acquisition
Sentiment note

Being acquired by Novo Nordisk for $4.7 billion, with promising drug candidate in Phase 3 trials for metabolic dysfunction treatment

Neutral GlobeNewswire Inc. • Juan Monteverde
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)

Law firm Monteverde & Associates is investigating the proposed merger of Akero Therapeutics with Novo Nordisk, where shareholders will receive $54.00 per share in cash and a potential additional $6.00 per share contingent on regulatory approval.

AKRO NVO merger acquisition shareholder investigation regulatory approval
Sentiment note

The merger offers a cash payment with potential additional value, but the law firm is investigating whether the deal is fair to shareholders

Neutral GlobeNewswire Inc. • Halper Sadeh Llc
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates AKRO, CCRD, AL, PBBK on Behalf of Shareholders

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches in several corporate transactions involving Akero Therapeutics, CoreCard, Air Lease, and PB Bankshares.

AKRO CCRD AL PBBK shareholder rights securities law corporate transactions mergers
Sentiment note

Proposed sale to Novo Nordisk with cash and contingent value right, potential investigation suggests possible procedural concerns

Positive Benzinga • Vandana Singh
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion

Novo Nordisk will acquire Akero Therapeutics for $54 per share in cash, totaling approximately $4.7 billion, with potential additional payment of $0.5 billion upon U.S. regulatory approval of EFX for treating liver disease.

NVO AKRO acquisition liver disease metabolic dysfunction pharmaceutical merger
Sentiment note

Receiving significant acquisition premium of $54 per share and potential additional $6 per share contingent on regulatory approval

Positive Benzinga • Globe Newswire
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, offering $54 per share in cash and a potential additional $6 per share contingent on regulatory approval of efruxifermin by June 30, 2031.

AKRO NVO acquisition metabolic diseases MASH pharmaceutical clinical stage
Sentiment note

Receiving significant premium (32-57%) on share price, board unanimously approved transaction, and potential for expanded treatment options

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal